2QM0 Stock Overview
A technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Xylo Technologies Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.51 |
| 52 Week High | US$2.22 |
| 52 Week Low | US$1.32 |
| Beta | 1.49 |
| 11 Month Change | -6.79% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -24.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2QM0 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0.7% | -0.5% | 0.9% |
| 1Y | n/a | 2.3% | 5.7% |
Return vs Industry: Insufficient data to determine how 2QM0 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how 2QM0 performed against the German Market.
Price Volatility
| 2QM0 volatility | |
|---|---|
| 2QM0 Average Weekly Movement | 15.0% |
| Medical Equipment Industry Average Movement | 4.2% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2QM0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 2QM0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 84 | Liron Carmel | www.medigus.com |
Xylo Technologies Ltd, a technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally. The company operates through Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Others segments. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease.
Xylo Technologies Ltd Fundamentals Summary
| 2QM0 fundamental statistics | |
|---|---|
| Market cap | €3.15m |
| Earnings (TTM) | -€14.78m |
| Revenue (TTM) | €84.62m |
0.0x
P/S Ratio-0.2x
P/E RatioIs 2QM0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2QM0 income statement (TTM) | |
|---|---|
| Revenue | US$91.72m |
| Cost of Revenue | US$79.88m |
| Gross Profit | US$11.84m |
| Other Expenses | US$27.87m |
| Earnings | -US$16.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.46 |
| Gross Margin | 12.91% |
| Net Profit Margin | -17.47% |
| Debt/Equity Ratio | 28.4% |
How did 2QM0 perform over the long term?
See historical performance and comparison